Compare RGP & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | NYXH |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.7M | 91.6M |
| IPO Year | 2000 | 2021 |
| Metric | RGP | NYXH |
|---|---|---|
| Price | $2.65 | $0.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $6.50 | $2.80 |
| AVG Volume (30 Days) | ★ 261.7K | 254.5K |
| Earning Date | 01-06-2027 | 11-05-2026 |
| Dividend Yield | ★ 10.41% | N/A |
| EPS Growth | ★ 79.14 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $452,006,000.00 | N/A |
| Revenue This Year | N/A | $234.49 |
| Revenue Next Year | $8.19 | $98.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.33 | $0.80 |
| 52 Week High | $5.37 | $5.39 |
| Indicator | RGP | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 36.80 |
| Support Level | $2.58 | $0.80 |
| Resistance Level | $2.85 | $0.97 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 24.07 | 68.99 |
Resources Connection Inc is a professional services firm. Its segments include On-Demand Talent provides businesses with a go-to source for bringing in experts when its needed, serving the office of the CFO; Consulting drives transformation across people, processes and technology across domain areas including finance, technology and digital, risk and compliance and operational performance; Europe & Asia Pacific offers both on-demand and consulting services to clients throughout Europe and Asia Pacific; Outsourced Services; and Sitrick. It derives the majority of revenue from On-Demand Talent segment. Geographically, it operates in United States and internationally.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.